ORLANDO, FL—The latest-generation HeartMate left ventricular assist device has beat out its predecessor with results so promising that at least one observer is raising the question of whether it’s ...

March 12 (UPI) --The HeartMate 3, an update to one of the most widely-used left ventricle assist devices, or LVADs, in the world, showed strong long-term results during a large clinical trial, its ...

MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...

Thoratec Corp.THOR recently announced that it has received a conditional approval from the Food and Drug Administration (FDA) for a U.S. IDE clinical trial to investigate the use of its HeartMate PHP ...

Abbott announced on October 19, 2018 that its HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living ...

PLEASANTON, Calif., Thoratec Corporation, a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced the first ever HeartMate 3™ implant ...

WASHINGTON, DC — One-year results from the HeartMate 3 (Thoratec/St Jude Medical) left ventricular assist device (LVAD) CE Mark Trial continued to build upon its positive 6-month findings announced ...

A life-saving heart pump that has helped more than 30,000 people worldwide live longer, more active lives is now the subject of a serious recall. Abbott is recalling its HeartMate II and HeartMate 3 ...

SAN DIEGO — Patients with advanced heart disease who received the HeartMate 3 left ventricular assist device had fewer clotting and bleeding events at 6 months than similar patients who received the ...

Abbott Laboratories, which acquired Minnesota medical device maker St. Jude Medical last month, is halting use of a commercially promising blood pump in the U.S. and Europe following a patient death ...

Thoratec ($THOR) credited a U.S. and global sales surge of its HeartMate II pump as a key factor in boosting 2012 first-quarter revenue 27% versus a year earlier. As ...